While some trials show no major changes in BMD, others suggest slight improvements in bone turnover markers: Trials of liraglutide and exenatide generally show stable BMD over 612 months Certain populations such as postmenopausal women or individuals with rapid weight loss may show changes in bone markers like osteocalcin and P1NP However, most of these studies are small, short-term, or not powered for skeletal endpoints
The tool also outlines next steps the patient can take, like getting started with Ro's GLP-1 program or sending a link with the findings to their doctor
Not surprisingly, a subset of DPP-4 inhibitors evaluated during pre-clinical development were found to suppress DPP-8 and/or DPP-9 activity, causing severe toxicities, including weakened T cell activation and proliferation, impaired preadipocyte differentiation (Han et al., 2015), enlarged lymph nodes, splenomegaly, etc
Your doctor will consider several factors before prescribing it: Medical History: Conditions like a history of thyroid cancer, pancreatitis, or severe gastrointestinal issues may make semaglutide unsafe
02105-1/asset/8468e457-0c7f-4e4c-9b6d-2202dbefa9cb/main.assets/gr1_lrg.jpg)
